ClinicalTrials.gg
CompletedNCT00406809Updated Aug 2, 2021

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

A Phase 1/2 interventional study of ABT-263 in Chronic Lymphoid Leukemia, Lymphoid Malignancies and Non-Hodgkin's Lymphoma, sponsored by AbbVie (prior sponsor, Abbott). Completed at 12 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-08-02.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
81
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Leukemia, B-Cell with a site in United States — 21 open to participants now, 34 under way, 4 of them phase 3. Leukemia, B-Cell · United States.

Enrollment
28th of 74
81 · median 53
Started
2006
with 2 others
Phase 1/2
13 of 79
4 open now
Registered
4th of 79
by date

Among the 79 studies in Leukemia, B-Cell with a site in United States, this one is the 28th largest by enrollment of the 74 interventional ones that give a count, is one of 3 that started in 2006, is one of 13 in phase 1/2, and was the 4th registered.

Leukemia, B-Cell

191 studies on the registry are indexed under Leukemia, B-Cell; 53 are open to participants now.

Browse Leukemia, B-Cell studies →

Open to participants now

21 of the 79 studies in Leukemia, B-Cell with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Leukemia, B-Cell studies recruiting now, 19 (48%) set no upper age limit and 16 (40%) stop at 75 or younger; 16 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Leukemia, B-Cell with a site in United States, or all of them as a file.
02

Study summary

The Phase 1 portion of the study evaluated the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose in subjects with lymphoid malignancies. The Phase 2a portion of the study is evaluating ABT-263 using a step-up dosing regimen and may be increased to the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy in subject with lymphoid malignancies. The Extension portion of the study is to allow Phase 2a subjects who remain active 1 year after the last subject enrolls or who have been on study approximately 1 year to continue receiving ABT-263 with less frequent study evaluations. Subjects in the Extension Study will continue receiving study drug for up to 7 years after the last subject transitions to the Extension Study, or until disease progression or toxicity that necessitates discontinuation (whichever comes first).

Read the detailed description

Enrollment breakdown: Entered Study: Phase 1a: 39; Phase 1b: 19; Phase 2a: 33; Total: 91 Entered Treatment: Phase 1a: 38; Phase 1b: 17; Phase 2a: 26; Total: 81

03

Conditions studied

  • Chronic Lymphoid Leukemia
  • Lymphoid Malignancies
  • Non-Hodgkin's Lymphoma
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Peripheral T-cell Lymphoma

Keywords

  • Sezary syndrome
  • cutaneous T-cell lymphoma
  • follicular lymphoma
  • marginal zone lymphoma
  • indolent T-cell lymphoma
  • Navitoclax
  • Non-Hodgkin's lymphoma
  • peripheral T-cell lymphoma
  • ABT-263
  • lymphoid malignancies
  • chronic lymphoid leukemia
  • mycosis fungoides
  • mantle cell lymphoma
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnoses:

    • 1a/1b - lymphoid ;
    • 2a, Arm A - follicular lymphoma;
    • 2a, Arm B - mantle cell, peripheral or cutaneous T-cell lymphomas including mycosis fungoides and Sezary syndrome or other indolent B-cell lymphomas such as marginal zone lymphoma;
  • Received at least 1 prior chemotherapy treatment regimen (P1a/1b) and disease (P2a).
  • (ECOG) score of \<= 1.
  • Magnetic Resonance Imaging (MRI)/computed tomography (CT) negative for subdural or epidural hematoma w/in 28 days prior to first dose, if clinically indicated.
  • Stable dose of Selective serotonin reuptake inhibitors (SSRI) antidepressants for at least 21 days prior to 1st dose.
  • Adequate bone marrow (BM) independent of any growth factor support (except with heavily infiltrated bone marrow (80% or more)):

    • (ANC) >= 1000/µL;
    • >= 100,000/mm3 (entry count must be independent of transfusion with in 14 days of Screening);
    • >= 9.0/dL.
  • Adequate coagulation, renal, and hepatic function:

    • Serum creatinine \<= 2.0 mg/dL or calculated >= 50 mL/min;
    • (AST) and alanine aminotransferase (ALT) \<= 3.0 x (ULN);
    • \<= 1.5 x ULN;
    • Gilbert's Syndrome may have a bilirubin > 1.5 x ULN;
    • Coagulation: (aPTT), Prothrombin Time (PT), not to exceed 1.2 x ULN
  • Females must be surgically sterile, (at least 1 year), or negative results for a pregnancy test performed at Screening on a serum sample obtained with in 14 days prior to initial dose, and prior to dosing on a urine sample obtained on C1 D-3 (P1a) or Lead-in D1 (P1b, P2a) if > 7 days since serum results.
  • Females not surgically sterile or postmenopausal (at least 1 year) and non-vasectomized males must practice .
  • P2a only: History of stem cell transplant must be > 6 months post transplant with adequate BM independent of growth factor support per lab reference range at Screening as follows:

    • Absolute Neutrophil Count (ANC) >= 1,500/µL;
    • Platelets >= 125,000/mm3 (entry platelet count must be independent of transfusion with in 14 days of Screening);
    • Hemoglobin >= 10.0g/dL;
  • by International Working Group (IWG)/National Cancer Institute- sponsored Working Group (NCI-WG) criteria.
  • At least one of following for Pharmacodynamics (P2a):

    • archived diagnostic Formalin Fixed Paraffin Embedded (FFPE) tumor tissue with no intervening treatment since ,
    • core needle biopsy of malignant lymph node, or
    • bone marrow aspirate or core positive for lymphoma.

Extension Study Inclusion Criteria Phase 2a subjects who enter the Extension Study must continue to meet all Inclusion and Exclusion criteria, with the exception of Inclusion Criterion regarding measurable disease by International Working Group (IWG)/National Cancer Institute- sponsored Working Group (NCI-WG) criteria and Inclusion Criteria regarding laboratory parameters for hematology, coagulation, and chemistry. Subjects entering the Extension Study must also have stable lab values per applicable laboratory reference ranges. In addition, subjects must also meet the following criteria:

  • Subjects must meet the following hematology and coagulation lab criteria:

    • Platelet counts must be >= 25,000/mm3 (untransfused). Platelet counts \<= 50,000/mm3 must be stable and monitored at an increased frequency at the discretion of the investigator.
    • Absolute Neutrophil count (ANC) >= 500/µL. ANC >= 500/µL and \< 1,000/µL should be monitored at an increased frequency at the discretion of the investigator.
    • Hemoglobin of >= 8.0 g/dL.
    • aPTT, PT is not to exceed 1.2 x ULN.
  • Chemistry values must not exceed Grade 2. Grade 2 chemistry labs should be monitored at an increased frequency at the discretion of the investigator. Subjects must meet the following chemistry criteria:

    • Serum creatinine \<= 3.0 x the upper normal limit (ULN) of institution's normal range. * AST and ALT \<= 5.0 x the upper normal limit (ULN) of institution's normal range.
    • Bilirubin \<= 3.0 x ULN. Subjects with Gilbert's Syndrome may be allowed to have a Bilirubin > 3.0 x ULN based on a joint decision between the investigator and Abbott medical monitor.

Exclusion criteria

Exclusion Criteria:

  • History of, or is, clinically suspicious for cancer-related Central Nervous System (CNS) disease, lymphoid or non-lymphoid.
  • Undergone an or autologous stem cell transplant.
  • Underlying, predisposing condition of bleeding or currently exhibits signs of bleeding.
  • Recent history of non-chemotherapy induced thrombocytopenic associated bleeding with in 1 year prior to first dose.
  • Active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
  • Active immune thrombocytopenic purpura or history of being to transfusions with in 1 year prior to first dose.
  • Significant history of cardiovascular disease, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease.
  • Females pregnant or breast-feeding.
  • Positive for (HIV)
  • History of other active with in the past 3 years (P1a/1b) or past 5 years (P2a), except adequately treated in situ carcinoma of the cervix uteri; basal or squamous cell carcinoma; in situ carcinoma of the bladder; previous malignancy confined and surgically resected with curative intent.
  • Evidence of other clinically significant uncontrolled condition(s), including, but not limited to active systemic fungal infection; diagnosis of fever and neutropenia with in 1 week prior to study drug.
  • Received therapy with in 7 days prior to 1st dose of study drug for anti-neoplastic intent.
  • Received any anti-cancer therapy, including chemotherapy, immunotherapy, radiotherapy, hormonal or any therapy, with in 14 days prior to first dose of study drug, or has not recovered to \<Gr2 clinically significant AE(s) /toxicity(s) of the previous therapy.
  • Received a biologic with in 30 days prior to first dose.
  • Currently receiving or requires anticoagulation therapy or any drugs or herbal supplements that affect platelet function, with the exception of low-dose anticoagulation medications that are used to maintain the patency of a central venous catheter.
  • Received aspirin with in 7 days prior to first dose and during ABT-263 administration.
  • Consumed grapefruit or grapefruit products with in 3 days prior to first dose.
  • P1a/1b only: Diagnosed with Posttransplant lymphoproliferative disorder (PTLD); Burkitt's, Burkitt-like, or HIV-associate lymphoma; lymphoblastic lymphoma/leukemia; or multiple myeloma.
  • Subject has received inhibitors (e.g., ketoconazole, clarithromycin) within 7 days prior to the administration of the first dose of ABT-263 (P2a).
  • Subject had a prior significant toxicity from another Bcl-2 family protein inhibitor (P2a).
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Phase 1a and 1b

    Relapsed or refractory lymphoid malignancies

    Drug: ABT-263

  • Experimental
    Arm A (Phase 2a)

    Relapsed or refractory follicular lymphoma

    Drug: ABT-263

  • Experimental
    Arm B (Phase 2a)

    Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma

    Drug: ABT-263

  • Experimental
    Extension Study

    Relapsed or refractory follicular lymphoma or Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma

    Drug: ABT-263

Interventions

  • DrugNavitoclaxStudies of NavitoclaxNavitoclax pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral solution Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing. Oral solution and tablets Phase 2a dosing under 21 day continuous dosing. - 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.

06

What researchers measure

Primary outcomes

  1. Phase 1a: Determine dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) and schedule - intermittent dosing.

    1a: Determination of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) under a 14/21 day dosing schedule

    Time frame: Repeating sequence of 14 days on therapy and 7 days off.

  2. Phase 1b: Determine dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) and schedule - continuous dosing.

    Phase 1b: Determination of ABT-263 dose limiting toxicity (DLT) and maximum tolerated dose (MTD) under a 21 day continuous dosing schedule.

    Time frame: 21 day continuous dosing.

  3. Phase 2a: Continued assessment of safety profile at the recommended Phase 2 dose (RPTD) and schedule - continuous dosing.

    Phase 2a: Continued assessment of the safety profile of ABT-263 at the Recommended Phase 2 Dose (RPTD) and schedule under a 21 day continuous dosing.

    Time frame: 21 day continuous dosing.

  4. Phase 2a: Assessment of preliminary efficacy signals including biomarker assessment - continuous dosing.

    Phase 2a: Assessment of the preliminary efficacy signals of ABT-263, including biomarker assessment, at the Recommended Phase 2 Dose (RPTD) and schedule under a 21 day continuous dosing.

    Time frame: 21 day continuous dosing.

  5. Extension Study: Continued assessment of the safety profile of ABT-263

    Continued assessment of the safety profile of ABT-263.

    Time frame: 21 day continuous dosing

  6. Extension Study: Continued assessment of the preliminary efficacy signals of ABT-263.

    Continued assessment of the preliminary efficacy signals of ABT-263.

    Time frame: day continuous dosing

Secondary outcomes

  1. Phase 1a or Phase 1b safety assessment

    Assessment of the safety of ABT-263

    Time frame: Repeating sequence of 14 days on therapy and 7 days off OR 21 day continuous dosing.

  2. Phase 1a, Phase 1b, or Phase 2a pharmacokinetic profile evaluation

    Evaluation of pharmacokinetic profile of ABT-263.

    Time frame: Repeating sequence of 14 days on therapy and 7 days off OR 21 day continuous dosing.

  3. Phase 1a effect of food on bioavailability

    Evaluation of the effect of food on bioavailability

    Time frame: Repeating sequence of 14 days on therapy and 7 days off.

07

Study locations

12 sites
  • Site Reference ID/Investigator# 4997
    Los Angeles, California 90033, United States
  • Site Reference ID/Investigator# 9104
    Los Angeles, California 90095, United States
  • Site Reference ID/Investigator# 2613
    Bethesda, Maryland 20892, United States
  • Site Reference ID/Investigator# 40243
    Boston, Massachusetts 02215, United States
  • Site Reference ID/Investigator# 4745
    Boston, Massachusetts 02215, United States
  • Site Reference ID/Investigator# 2628
    Buffalo, New York 14263, United States
  • Site Reference ID/Investigator# 23543
    New York, New York 10016, United States
  • Site Reference ID/Investigator# 2627
    New York, New York 10021, United States
  • Site Reference ID/Investigator# 2614
    New York, New York 10032, United States
  • Site Reference ID/Investigator# 5383
    New York, New York 10065, United States
  • Site Reference ID/Investigator# 12306
    Rochester, New York 14642, United States
  • Site Reference ID/Investigator# 8941
    Edmonton, T6G 1Z2, Canada
08

References and documents

Publications

  • Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010 Dec;11(12):1149-59. doi: 10.1016/S1470-2045(10)70261-8. Epub 2010 Nov 18. PubMed 21094089 ↗
  • de Vos S, Leonard JP, Friedberg JW, Zain J, Dunleavy K, Humerickhouse R, Hayslip J, Pesko J, Wilson WH. Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leuk Lymphoma. 2021 Apr;62(4):810-818. doi: 10.1080/10428194.2020.1845332. Epub 2020 Nov 25. PubMed 33236943 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2006
First posted
Dec 4, 2006
Start
Nov 2006
Primary completionActual
Oct 2016
CompletionActual
Oct 2016
Results delay requested
Oct 31, 2017
Last update
Aug 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00406809
Responsible party
Sponsor
First posted
Dec 4, 2006
Start date
Nov 2006
Primary completion
Oct 2016
Completion
Oct 2016
Last update
Aug 2, 2021

Study contacts

Mack Mabry, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navitoclax

Start the discussion